|
|
|
| home > white papers > Maximize the ROI of Your Post-Approval Research - Bioclinica |
|
|
 WHITE PAPERS |
|
|
Bioclinica
|
|
Maximize the ROI of Your Post-Approval Research
|
|
Expenditures in post-approval (Phase IV) research are going up across
the pharmaceutical, biotech and medical device industries. Given the
resources you’ve committed to post-approval research, you may be
wondering if you’re getting the greatest possible return on your
investment.
Discover how to harness the power of post-approval
research to increase data collection, reduce resource burn, save money,
and maximize your ROI!
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Everything Genetic launches Next Generation Sequencing service as part of its public-private partnership with Berkshire and Surrey Pathology Services
NANTWICH, CHESHIRE and GUILDFORD, SURREY, NOVEMBER 2022. Everything
Genetic, a fast-growing UK business offering genetic testing services
for the diagnosis, prevention and treatment of a range of cancers, has
partnered with Berkshire and Surrey Pathology Services (BSPS), an NHS
Pathology Network, to provide Next Generation Sequencing (NGS) services
to healthcare professionals and customers across the UK.
More info >> |
|
 |
White Papers |
 |
|
Accelerating the Time from DNA to Material
Merck
Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >> |
|
|
|
